社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
PapiChulo88
IP属地:未知
+关注
帖子 · 36
帖子 · 36
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
PapiChulo88
PapiChulo88
·
2021-12-17
Oh my
BKKT Stock Alert: Why Is Bakkt Plunging<blockquote>BKKT股票提醒:Bakkt为何暴跌</blockquote>
Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exch
BKKT Stock Alert: Why Is Bakkt Plunging<blockquote>BKKT股票提醒:Bakkt为何暴跌</blockquote>
看
1,878
回复
评论
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
Wow
非常抱歉,此主贴已删除
看
2,540
回复
评论
点赞
2
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
Wow
@王春龙Bale:
今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。$小米集团-W(01810)$$苹果(AAPL)$
今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。$小米集团-W(01810)$$苹果(AAPL)$
看
2,031
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
🥺
@名字就是这样:
$Bionano Genomics(BNGO)$买定离手[可爱] [可爱]
$Bionano Genomics(BNGO)$买定离手[可爱] [可爱]
看
2,060
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
😭
非常抱歉,此主贴已删除
看
2,103
回复
1
点赞
2
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-09
$Naked Brand(NAKD)$
is up!
看
2,123
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-05
Oh my
Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>
Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $
Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>
看
2,293
回复
评论
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-01
$HCW Biologics Inc.(HCWB)$
Hold! It will be up again
看
2,058
回复
评论
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-01
$Naked Brand(NAKD)$
What’s happening
看
1,962
回复
1
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-10-27
It’s a good time to buy
Trump stocks fell sharply in premarket trading<blockquote>特朗普股价在盘前交易中大幅下跌</blockquote>
Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%
Trump stocks fell sharply in premarket trading<blockquote>特朗普股价在盘前交易中大幅下跌</blockquote>
看
1,803
回复
评论
点赞
5
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576458191145383","uuid":"3576458191145383","gmtCreate":1613364167181,"gmtModify":1623129571224,"name":"PapiChulo88","pinyin":"papichulo88","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":12,"tweetSize":36,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":690797621,"gmtCreate":1639707049357,"gmtModify":1639708339012,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"Oh my ","listText":"Oh my ","text":"Oh my","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690797621","repostId":"1155708308","repostType":2,"repost":{"id":"1155708308","kind":"news","pubTimestamp":1639706709,"share":"https://www.laohu8.com/m/news/1155708308?lang=zh_CN&edition=full","pubTime":"2021-12-17 10:05","market":"us","language":"en","title":"BKKT Stock Alert: Why Is Bakkt Plunging<blockquote>BKKT股票提醒:Bakkt为何暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1155708308","media":"InvestorPlace","summary":"Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exch","content":"<p><div> Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exchange Commission (SEC) filing has investors spooked. BKKT stock is down big today, just two months ...</p><p><blockquote><div>数字资产管理公司Bakkt(纽约证券交易所股票代码:BKKT)周四直线下跌,此前美国证券交易委员会(SEC)最近提交的一份文件吓坏了投资者。BKKT股票今天大幅下跌,仅两个月...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BKKT Stock Alert: Why Is Bakkt Plunging<blockquote>BKKT股票提醒:Bakkt为何暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBKKT Stock Alert: Why Is Bakkt Plunging<blockquote>BKKT股票提醒:Bakkt为何暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-17 10:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exchange Commission (SEC) filing has investors spooked. BKKT stock is down big today, just two months ...</p><p><blockquote><div>数字资产管理公司Bakkt(纽约证券交易所股票代码:BKKT)周四直线下跌,此前美国证券交易委员会(SEC)最近提交的一份文件吓坏了投资者。BKKT股票今天大幅下跌,仅两个月...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BKKT":"Bakkt Holdings, Inc."},"source_url":"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155708308","content_text":"Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exchange Commission (SEC) filing has investors spooked. BKKT stock is down big today, just two months after its October SPAC debut.\nSo, what’s causing this slump in Bakkt?\nBakkt is falling victim to an apparent PIPE (private investment in public equity) selloff. Yesterday, Bakkt filed an S-1 registration statement with the SEC, allowing early investors in the company freedom to sell their stake. Consequently, they did. Bakkt has already shed more than 31% of its share price as investors cool off on the once red-hot stock.\nFounded in 2018, Bakkt went public just this past October. A week after its debut, BKKT went as high as $42.52 per share amid sky-high investor interest. However, it seems the party is over. Accounting for today’s losses so far, Bakkt is trending a bit below $10 at the time of writing.\nWhat else do you need to know about Bakkt’s dive?\nBKKT Stock Flounders as Bears Come Out on Top\nWhile the PIPE unlocking is wreaking havoc on shareholder wallets, Bakkt is grasping at straws to put a stop to the decline.\nThe Georgia-based company is best known for its digital asset exchange platform. Bakkt is the latest crypto exchange making waves after its app launched under the guidance of parent company Intercontinental Exchange.\nUnfortunately, since its Oct. 25 peak, it’s been a downhill story for the crypto exchange. Even despite a headline-grabbing integration announcement with Alphabet’s Google Pay, Bakkt can’t seem to reverse its fortune.\nAdditionally, just this week Bakkt began offering WyndhamRewards members the ability to convert reward points into cash deposited directly into their accounts. Unfortunately, it was seemingly to no avail.\nTime will tell just how far BKKT will drop. However, for those looking for cheap crypto exposure, a rock-bottom entry point like this could be appealing.","news_type":1,"symbols_score_info":{"BKKT":0.9}},"isVote":1,"tweetType":1,"viewCount":1878,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690704308,"gmtCreate":1639706305167,"gmtModify":1639706953509,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690704308","repostId":"1172405131","repostType":4,"isVote":1,"tweetType":1,"viewCount":2540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690705530,"gmtCreate":1639706274621,"gmtModify":1639706274754,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690705530","repostId":"604088904","repostType":1,"repost":{"id":604088904,"gmtCreate":1639281345798,"gmtModify":1639358988582,"author":{"id":"3494378197296027","authorId":"3494378197296027","name":"王春龙Bale","avatar":"https://static.tigerbbs.com/11e561afcd6e41b0d7953fc87b7c54a9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3494378197296027","idStr":"3494378197296027"},"themes":[],"htmlText":"今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a><a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>","listText":"今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a><a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>","text":"今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。$小米集团-W(01810)$$苹果(AAPL)$","images":[{"img":"https://static.tigerbbs.com/4c8eac165d2046bc5473d6c25feeb539","width":"1080","height":"1611"},{"img":"https://static.tigerbbs.com/869ac9acb00e1ad37f873af33834623c","width":"1000","height":"705"},{"img":"https://static.tigerbbs.com/64235d5f2b7b09ae46076a8da4715361","width":"1000","height":"643"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604088904","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2031,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690701170,"gmtCreate":1639706008518,"gmtModify":1639706008640,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"🥺","listText":"🥺","text":"🥺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690701170","repostId":"607460968","repostType":1,"repost":{"id":607460968,"gmtCreate":1639579382045,"gmtModify":1639704589453,"author":{"id":"3559804133107604","authorId":"3559804133107604","name":"名字就是这样","avatar":"https://static.tigerbbs.com/ecd5018dcfd0f98e2db33cd5b25c541c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559804133107604","idStr":"3559804133107604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>买定离手[可爱] [可爱] ","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>买定离手[可爱] [可爱] ","text":"$Bionano Genomics(BNGO)$买定离手[可爱] [可爱]","images":[{"img":"https://static.tigerbbs.com/46343c9bd8b490ff7fcdbb048c54a4e2","width":"750","height":"1334"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607460968","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2060,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690703919,"gmtCreate":1639705922440,"gmtModify":1639705922561,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"😭","listText":"😭","text":"😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690703919","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":2103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844822526,"gmtCreate":1636417891085,"gmtModify":1636417891215,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>is up! ","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>is up! ","text":"$Naked Brand(NAKD)$is up!","images":[{"img":"https://static.tigerbbs.com/5082d8e62ecba911cc847ce3b96ab592","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844822526","isVote":1,"tweetType":1,"viewCount":2123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846430950,"gmtCreate":1636102914954,"gmtModify":1636102915010,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"Oh my ","listText":"Oh my ","text":"Oh my","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846430950","repostId":"1194946622","repostType":4,"repost":{"id":"1194946622","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636101187,"share":"https://www.laohu8.com/m/news/1194946622?lang=zh_CN&edition=full","pubTime":"2021-11-05 16:33","market":"us","language":"en","title":"Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194946622","media":"Tiger Newspress","summary":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $","content":"<p>Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.</p><p><blockquote>Bionano Genomics第三季度净亏损2075.3万美元,销售额466万美元,超出预期423万美元,Bionano Genomics股价在盘前交易中下跌超过8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> <b>Bionano Genomics, Inc.</b> reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.</p><p><blockquote><b>生物纳米基因组学公司。</b>报告了截至2021年9月30日的季度财务业绩和业务成就,并重点介绍了最近的公司更新。</blockquote></p><p> <i>– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics</i></p><p><blockquote><i>-收购BioDiscovery将Bionano从结构变异公司转变为数据解决方案提供商,有潜力提供基因组学领域最全面的变异分析平台</i></blockquote></p><p> <i>– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base</i></p><p><blockquote><i>-在Saphyr增长的推动下,总收入为470万美元,总收入同比增长112%®已安装底座</i></blockquote></p><p> <i>– Record number of Saphyr shipments and installations for any quarter to date</i></p><p><blockquote><i>-迄今为止任何季度Saphyr发货和安装数量均创历史新高</i></blockquote></p><p> <i>– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications</i></p><p><blockquote><i>-推出用于产前应用的羊膜穿刺术和绒毛取样(CVS)中超高分子量DNA分离方案</i></blockquote></p><p> <i>– Remaining 2021 milestones on track</i></p><p><blockquote><i>-2021年剩余里程碑步入正轨</i></blockquote></p><p> <i>– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021</i></p><p><blockquote><i>-截至2021年9月30日,资产负债表强劲,现金和短期投资为3.261亿美元</i></blockquote></p><p> “We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.</p><p><blockquote>“我们经历了Bionano历史上最强劲的季度,Saphyr的出货量和安装量创历史新高,包括在几个著名地点的采用,包括世界各地的领先医院、细胞遗传学实验室和学术医疗中心。随着收购BioDiscovery,这是一家领先的软件公司,为基因组学数据的分析、可视化、解释和报告提供一流的解决方案。对于微阵列和下一代测序(NGS),我们正在将Bionano Genomics从结构变异公司转变为数据解决方案提供商。我们相信,这将通过软件利用NGS市场来扩大市场机会。我们对我们所取得的进展以及杰出的领导者加入Bionano与我们一起改变世界看待基因组的方式感到非常高兴。”Bionano Genomics首席执行官Derik Holmlin博士评论道。</blockquote></p><p> Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”</p><p><blockquote>Bionano首席财务官克里斯·斯图尔特补充说:“第三季度是另一个出色的季度。我们继续实现收入同比有意义的增长,截至本季度末,我们保持着3.26亿美元现金和有价证券的强劲资产负债表。我们还继续实现我们在2021年第一季度制定的里程碑。”</blockquote></p><p> <b>Key Business Highlights in Q3</b></p><p><blockquote><b>第三季度主要业务亮点</b></blockquote></p><p> The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:</p><p><blockquote>该公司执行其商业化战略,通过在关键科学会议上展示数据来建立科学势头,并推动全球关键机构对Saphyr的利用,重点如下:</blockquote></p><p> –<b> Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3</b>. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.</p><p><blockquote>–<b>将Saphyr系统的安装数量从第二季度末的121个扩大到第三季度末的141个</b>截至2021年9月30日的季度,我们总共向现场运送了24套Saphyr系统,而2020年同季度运送了11套系统。</blockquote></p><p> –<b> Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,</b>which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.</p><p><blockquote>–<b>截至2021年9月30日的季度售出3,969个纳米通道阵列流通池,</b>这是有史以来任何季度销售最多的流动池,比2020年同季度增长了122%。</blockquote></p><p> –<b> Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applications</b>supporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.</p><p><blockquote>–<b>用于产前应用的超高分子量DNA分离溶液的商业化发布</b>支持使用来自羊膜穿刺术和CVS的样本。Bionano Prep SP羊膜和CVS培养DNA分离方案支持新鲜培养物和冷冻保存细胞,这扩大了OGM的市场。</blockquote></p><p> – <b>OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centers</b>inthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.</p><p><blockquote>– <b>几个著名的细胞遗传学实验室和学术医学中心采用了带有Saphyr的OGM</b>在美国,包括布莱根妇女医院,该医院正在使用OGM来识别体质和癌症应用中的结构变异。在美国以外,Saphyr被澳大利亚、欧洲和中国采用。</blockquote></p><p> –<b> The largest clinical research study to date evaluating OGM was published in</b><b><i>The Journal of Molecular Diagnostics</i></b>for a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.</p><p><blockquote>–<b>迄今为止评估OGM的最大临床研究发表于</b><b><i>分子诊断学杂志</i></b>一种罕见的肌肉疾病,面肩肱肌营养不良症,或FSHD,在大约351名患者中。结果表明,与目前的Southern印迹分析的金标准方法相比,OGM提供的数据更快、更准确、更可重复。这些发现支持采用OGM作为Southern印迹分析的替代方案的基本原理,因为OGM具有更高的尺寸准确性以及与Southern印迹分析大于99%的一致性。</blockquote></p><p> –<b> NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,</b>Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.</p><p><blockquote>–<b>全球分子诊断领导者NuProbe Global采用Saphyr集成其专有工具,</b>定量扩增子测序(QASeq)和阻断剂置换扩增(BDA),用于生殖健康和肿瘤液体活检的研发工作。</blockquote></p><p></p><p> –<b> Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,</b>highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.</p><p><blockquote>–<b>Saphyr客户和Bionano在2021年8月中旬的年度癌症基因组学联盟会议上进行了10场演讲,</b>强调OGM在实体瘤分析、血液恶性肿瘤、受孕产物、产前和产后体质遗传学等临床研究应用中的益处。来自全球各地的500多名参与者以虚拟方式参加了会议,凸显了OGM对癌症基因组学的浓厚兴趣。</blockquote></p><p> – <b>Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021</b>, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.</p><p><blockquote>– <b>Bionano客户在2021年8月下旬的欧洲人类遗传学会(ESHG)会议上发表了11篇有关OGM的演讲</b>,展示了OGM在许多治疗应用领域的临床实用性,以及Bionano的Saphyr的独特能力®以相对于传统技术更高的分辨率检测整个基因组中所有类别的结构变异的系统。</blockquote></p><p> – <b>Added exceptional talent across commercial leadership functions,</b>includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.</p><p><blockquote>– <b>增加了跨商业领导职能的杰出人才,</b>包括全球客户体验副总裁Amanda Lettmannas、战略产品营销副总裁Alex Helmas、企业营销副总裁Stephanie Hoyleas、全球销售培训和发展副总裁Amanda Hernandezas、Lineagen副总裁兼总经理Justin Leightonas和Bob Hertsenbergas北美销售总监。</blockquote></p><p> <b>Financial Highlights</b></p><p><blockquote><b>财务摘要</b></blockquote></p><p> –<b> Total revenue for the third quarter of 2021 was$4.7 million,</b>up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.</p><p><blockquote>–<b>2021年第三季度总收入为470万美元,</b>比第二季度的390万美元增长21%,比2020年同期的220万美元增长112%。环比增长是由对我们的Saphyr光学基因组图谱解决方案的需求增加推动的,包括仪器销售的增加以及对我们的试剂租赁计划和消耗品的更大需求。同比增长是由产品销量增加和Lineagen收入增加推动的。</blockquote></p><p> –<b> Gross margin for the third quarter of 2021 was 24.8%,</b>compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.</p><p><blockquote>–<b>2021年第三季度毛利率为24.8%,</b>相比之下,上一季度为37.3%,2020年第三季度为33.4%。这一下降主要是由于实验室和保修相关费用的增加,预计这些费用将是非经常性的。</blockquote></p><p> –<b> Third quarter operating expense was$21.8 million,</b>compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.</p><p><blockquote>–<b>第三季度运营费用为2180万美元,</b>相比之下,上一季度为1790万美元,2020年第三季度为1100万美元。环比增长主要是由于员工人数和相关费用增加了180万美元,以及与扩大供应链以提高产量相关的研发费用增加了150万美元。第三季度运营费用包括280万美元的非现金股票薪酬。同比增长主要是由于我们构建组织的各个方面以支持我们预期的商业进展以及研发成本的增加,因此与员工相关的支出增加。</blockquote></p><p> – <b>AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 million</b>compared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.</p><p><blockquote>– <b>截至2021年9月30日,公司拥有现金、现金等价物和短期投资3.261亿美元</b>相比之下,2020年12月31日的现金和现金等价物为3840万美元。现金增加主要是由于2021年第一季度完成的股权融资。</blockquote></p><p> <b>Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr</b></p><p><blockquote><b>2021年剩余预期里程碑-推动全球采用Saphyr的举措</b></blockquote></p><p> – 4Q21: Interim publication of results from pediatric clinical study</p><p><blockquote>-4 Q21:儿科临床研究结果的中期公布</blockquote></p><p> – 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study</p><p><blockquote>-4 Q 21:在我们的产前临床研究和儿科临床研究中,3个研究中心对LDT的验证</blockquote></p><p> – 4Q21: Initial prototype of next gen high throughput Saphyr</p><p><blockquote>-4Q21:下一代高通量Saphyr的初始原型</blockquote></p><p> – 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020</p><p><blockquote>-21年第四季度:达到150套系统的安装基础,较2020年底增长50%</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-05 16:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.</p><p><blockquote>Bionano Genomics第三季度净亏损2075.3万美元,销售额466万美元,超出预期423万美元,Bionano Genomics股价在盘前交易中下跌超过8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> <b>Bionano Genomics, Inc.</b> reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.</p><p><blockquote><b>生物纳米基因组学公司。</b>报告了截至2021年9月30日的季度财务业绩和业务成就,并重点介绍了最近的公司更新。</blockquote></p><p> <i>– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics</i></p><p><blockquote><i>-收购BioDiscovery将Bionano从结构变异公司转变为数据解决方案提供商,有潜力提供基因组学领域最全面的变异分析平台</i></blockquote></p><p> <i>– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base</i></p><p><blockquote><i>-在Saphyr增长的推动下,总收入为470万美元,总收入同比增长112%®已安装底座</i></blockquote></p><p> <i>– Record number of Saphyr shipments and installations for any quarter to date</i></p><p><blockquote><i>-迄今为止任何季度Saphyr发货和安装数量均创历史新高</i></blockquote></p><p> <i>– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications</i></p><p><blockquote><i>-推出用于产前应用的羊膜穿刺术和绒毛取样(CVS)中超高分子量DNA分离方案</i></blockquote></p><p> <i>– Remaining 2021 milestones on track</i></p><p><blockquote><i>-2021年剩余里程碑步入正轨</i></blockquote></p><p> <i>– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021</i></p><p><blockquote><i>-截至2021年9月30日,资产负债表强劲,现金和短期投资为3.261亿美元</i></blockquote></p><p> “We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.</p><p><blockquote>“我们经历了Bionano历史上最强劲的季度,Saphyr的出货量和安装量创历史新高,包括在几个著名地点的采用,包括世界各地的领先医院、细胞遗传学实验室和学术医疗中心。随着收购BioDiscovery,这是一家领先的软件公司,为基因组学数据的分析、可视化、解释和报告提供一流的解决方案。对于微阵列和下一代测序(NGS),我们正在将Bionano Genomics从结构变异公司转变为数据解决方案提供商。我们相信,这将通过软件利用NGS市场来扩大市场机会。我们对我们所取得的进展以及杰出的领导者加入Bionano与我们一起改变世界看待基因组的方式感到非常高兴。”Bionano Genomics首席执行官Derik Holmlin博士评论道。</blockquote></p><p> Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”</p><p><blockquote>Bionano首席财务官克里斯·斯图尔特补充说:“第三季度是另一个出色的季度。我们继续实现收入同比有意义的增长,截至本季度末,我们保持着3.26亿美元现金和有价证券的强劲资产负债表。我们还继续实现我们在2021年第一季度制定的里程碑。”</blockquote></p><p> <b>Key Business Highlights in Q3</b></p><p><blockquote><b>第三季度主要业务亮点</b></blockquote></p><p> The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:</p><p><blockquote>该公司执行其商业化战略,通过在关键科学会议上展示数据来建立科学势头,并推动全球关键机构对Saphyr的利用,重点如下:</blockquote></p><p> –<b> Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3</b>. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.</p><p><blockquote>–<b>将Saphyr系统的安装数量从第二季度末的121个扩大到第三季度末的141个</b>截至2021年9月30日的季度,我们总共向现场运送了24套Saphyr系统,而2020年同季度运送了11套系统。</blockquote></p><p> –<b> Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,</b>which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.</p><p><blockquote>–<b>截至2021年9月30日的季度售出3,969个纳米通道阵列流通池,</b>这是有史以来任何季度销售最多的流动池,比2020年同季度增长了122%。</blockquote></p><p> –<b> Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applications</b>supporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.</p><p><blockquote>–<b>用于产前应用的超高分子量DNA分离溶液的商业化发布</b>支持使用来自羊膜穿刺术和CVS的样本。Bionano Prep SP羊膜和CVS培养DNA分离方案支持新鲜培养物和冷冻保存细胞,这扩大了OGM的市场。</blockquote></p><p> – <b>OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centers</b>inthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.</p><p><blockquote>– <b>几个著名的细胞遗传学实验室和学术医学中心采用了带有Saphyr的OGM</b>在美国,包括布莱根妇女医院,该医院正在使用OGM来识别体质和癌症应用中的结构变异。在美国以外,Saphyr被澳大利亚、欧洲和中国采用。</blockquote></p><p> –<b> The largest clinical research study to date evaluating OGM was published in</b><b><i>The Journal of Molecular Diagnostics</i></b>for a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.</p><p><blockquote>–<b>迄今为止评估OGM的最大临床研究发表于</b><b><i>分子诊断学杂志</i></b>一种罕见的肌肉疾病,面肩肱肌营养不良症,或FSHD,在大约351名患者中。结果表明,与目前的Southern印迹分析的金标准方法相比,OGM提供的数据更快、更准确、更可重复。这些发现支持采用OGM作为Southern印迹分析的替代方案的基本原理,因为OGM具有更高的尺寸准确性以及与Southern印迹分析大于99%的一致性。</blockquote></p><p> –<b> NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,</b>Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.</p><p><blockquote>–<b>全球分子诊断领导者NuProbe Global采用Saphyr集成其专有工具,</b>定量扩增子测序(QASeq)和阻断剂置换扩增(BDA),用于生殖健康和肿瘤液体活检的研发工作。</blockquote></p><p></p><p> –<b> Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,</b>highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.</p><p><blockquote>–<b>Saphyr客户和Bionano在2021年8月中旬的年度癌症基因组学联盟会议上进行了10场演讲,</b>强调OGM在实体瘤分析、血液恶性肿瘤、受孕产物、产前和产后体质遗传学等临床研究应用中的益处。来自全球各地的500多名参与者以虚拟方式参加了会议,凸显了OGM对癌症基因组学的浓厚兴趣。</blockquote></p><p> – <b>Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021</b>, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.</p><p><blockquote>– <b>Bionano客户在2021年8月下旬的欧洲人类遗传学会(ESHG)会议上发表了11篇有关OGM的演讲</b>,展示了OGM在许多治疗应用领域的临床实用性,以及Bionano的Saphyr的独特能力®以相对于传统技术更高的分辨率检测整个基因组中所有类别的结构变异的系统。</blockquote></p><p> – <b>Added exceptional talent across commercial leadership functions,</b>includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.</p><p><blockquote>– <b>增加了跨商业领导职能的杰出人才,</b>包括全球客户体验副总裁Amanda Lettmannas、战略产品营销副总裁Alex Helmas、企业营销副总裁Stephanie Hoyleas、全球销售培训和发展副总裁Amanda Hernandezas、Lineagen副总裁兼总经理Justin Leightonas和Bob Hertsenbergas北美销售总监。</blockquote></p><p> <b>Financial Highlights</b></p><p><blockquote><b>财务摘要</b></blockquote></p><p> –<b> Total revenue for the third quarter of 2021 was$4.7 million,</b>up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.</p><p><blockquote>–<b>2021年第三季度总收入为470万美元,</b>比第二季度的390万美元增长21%,比2020年同期的220万美元增长112%。环比增长是由对我们的Saphyr光学基因组图谱解决方案的需求增加推动的,包括仪器销售的增加以及对我们的试剂租赁计划和消耗品的更大需求。同比增长是由产品销量增加和Lineagen收入增加推动的。</blockquote></p><p> –<b> Gross margin for the third quarter of 2021 was 24.8%,</b>compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.</p><p><blockquote>–<b>2021年第三季度毛利率为24.8%,</b>相比之下,上一季度为37.3%,2020年第三季度为33.4%。这一下降主要是由于实验室和保修相关费用的增加,预计这些费用将是非经常性的。</blockquote></p><p> –<b> Third quarter operating expense was$21.8 million,</b>compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.</p><p><blockquote>–<b>第三季度运营费用为2180万美元,</b>相比之下,上一季度为1790万美元,2020年第三季度为1100万美元。环比增长主要是由于员工人数和相关费用增加了180万美元,以及与扩大供应链以提高产量相关的研发费用增加了150万美元。第三季度运营费用包括280万美元的非现金股票薪酬。同比增长主要是由于我们构建组织的各个方面以支持我们预期的商业进展以及研发成本的增加,因此与员工相关的支出增加。</blockquote></p><p> – <b>AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 million</b>compared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.</p><p><blockquote>– <b>截至2021年9月30日,公司拥有现金、现金等价物和短期投资3.261亿美元</b>相比之下,2020年12月31日的现金和现金等价物为3840万美元。现金增加主要是由于2021年第一季度完成的股权融资。</blockquote></p><p> <b>Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr</b></p><p><blockquote><b>2021年剩余预期里程碑-推动全球采用Saphyr的举措</b></blockquote></p><p> – 4Q21: Interim publication of results from pediatric clinical study</p><p><blockquote>-4 Q21:儿科临床研究结果的中期公布</blockquote></p><p> – 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study</p><p><blockquote>-4 Q 21:在我们的产前临床研究和儿科临床研究中,3个研究中心对LDT的验证</blockquote></p><p> – 4Q21: Initial prototype of next gen high throughput Saphyr</p><p><blockquote>-4Q21:下一代高通量Saphyr的初始原型</blockquote></p><p> – 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020</p><p><blockquote>-21年第四季度:达到150套系统的安装基础,较2020年底增长50%</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194946622","content_text":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.\n\nBionano Genomics, Inc. reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.\n– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics\n– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base\n– Record number of Saphyr shipments and installations for any quarter to date\n– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications\n– Remaining 2021 milestones on track\n– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021\n“We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.\nChris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”\nKey Business Highlights in Q3\nThe Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:\n– Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.\n– Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.\n– Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.\n– OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.\n– The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.\n– NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.\n– Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.\n– Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.\n– Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.\nFinancial Highlights\n– Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.\n– Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.\n– Third quarter operating expense was$21.8 million,compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.\n– AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.\nRemaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr\n– 4Q21: Interim publication of results from pediatric clinical study\n– 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study\n– 4Q21: Initial prototype of next gen high throughput Saphyr\n– 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020","news_type":1,"symbols_score_info":{"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":2293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849793486,"gmtCreate":1635776244013,"gmtModify":1635776244116,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HCWB\">$HCW Biologics Inc.(HCWB)$</a>Hold! It will be up again","listText":"<a href=\"https://laohu8.com/S/HCWB\">$HCW Biologics Inc.(HCWB)$</a>Hold! It will be up again","text":"$HCW Biologics Inc.(HCWB)$Hold! It will be up again","images":[{"img":"https://static.tigerbbs.com/9f78f1e45b52a24e3b5ad8e881f3d849","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849793486","isVote":1,"tweetType":1,"viewCount":2058,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849799713,"gmtCreate":1635776203533,"gmtModify":1635776203533,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>What’s happening ","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>What’s happening ","text":"$Naked Brand(NAKD)$What’s happening","images":[{"img":"https://static.tigerbbs.com/a9221a997ccd4e8a44354ac7a05795c6","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849799713","isVote":1,"tweetType":1,"viewCount":1962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":855989602,"gmtCreate":1635324421107,"gmtModify":1635324421107,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576458191145383","idStr":"3576458191145383"},"themes":[],"htmlText":"It’s a good time to buy ","listText":"It’s a good time to buy ","text":"It’s a good time to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855989602","repostId":"1105918886","repostType":4,"repost":{"id":"1105918886","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635322218,"share":"https://www.laohu8.com/m/news/1105918886?lang=zh_CN&edition=full","pubTime":"2021-10-27 16:10","market":"us","language":"en","title":"Trump stocks fell sharply in premarket trading<blockquote>特朗普股价在盘前交易中大幅下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105918886","media":"Tiger Newspress","summary":"Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%","content":"<p>Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%.<img src=\"https://static.tigerbbs.com/a94b366462004373a3f94a989d88dc52\" tg-width=\"285\" tg-height=\"124\" referrerpolicy=\"no-referrer\">Donald Trump has dropped from the Forbes 400 list of the richest Americans for the first time in 25 years, according to the Forbes list. Although Trump's current value of $2.5 billion is still worthy of being called \"super rich\", he is still $400 million short of the Forbes 400 Rich List in the past.</p><p><blockquote>特朗普股价在盘前交易中大幅下跌,Phunware下跌近10%,Creatd和DWAC下跌超过6%。根据福布斯排行榜,唐纳德·特朗普25年来首次跌出福布斯美国400富豪榜。尽管特朗普目前25亿美元的身价仍配得上被称为“超级富豪”,但他距离过去的福布斯400富豪榜还差4亿美元。</blockquote></p><p> Last week,Trump announced plans to set up his new social platform \"TRUTH Social\" and go public through SPAC company DWAC. While Phunware's software previously provided mobile applications for Trump campaign team.And recently,Creatd announced a new non-fungible token art drop through its OG Gallery unit consisting of three photographs of Trump. The NFT includes three candid images of a young Donald Trump, captured as he signs the breast of a model.</p><p><blockquote>上周,特朗普宣布计划成立自己的新社交平台“TRUTH Social”,并通过SPAC公司DWAC上市,而Phunware的软件此前曾为特朗普竞选团队提供移动应用。最近,Creatd通过其OG画廊部门宣布了一个新的不可替代的象征性艺术下降,由特朗普的三张照片组成。NFT包括三张年轻的唐纳德·特朗普在一名模特的胸部签名时拍摄的照片。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trump stocks fell sharply in premarket trading<blockquote>特朗普股价在盘前交易中大幅下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrump stocks fell sharply in premarket trading<blockquote>特朗普股价在盘前交易中大幅下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-27 16:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%.<img src=\"https://static.tigerbbs.com/a94b366462004373a3f94a989d88dc52\" tg-width=\"285\" tg-height=\"124\" referrerpolicy=\"no-referrer\">Donald Trump has dropped from the Forbes 400 list of the richest Americans for the first time in 25 years, according to the Forbes list. Although Trump's current value of $2.5 billion is still worthy of being called \"super rich\", he is still $400 million short of the Forbes 400 Rich List in the past.</p><p><blockquote>特朗普股价在盘前交易中大幅下跌,Phunware下跌近10%,Creatd和DWAC下跌超过6%。根据福布斯排行榜,唐纳德·特朗普25年来首次跌出福布斯美国400富豪榜。尽管特朗普目前25亿美元的身价仍配得上被称为“超级富豪”,但他距离过去的福布斯400富豪榜还差4亿美元。</blockquote></p><p> Last week,Trump announced plans to set up his new social platform \"TRUTH Social\" and go public through SPAC company DWAC. While Phunware's software previously provided mobile applications for Trump campaign team.And recently,Creatd announced a new non-fungible token art drop through its OG Gallery unit consisting of three photographs of Trump. The NFT includes three candid images of a young Donald Trump, captured as he signs the breast of a model.</p><p><blockquote>上周,特朗普宣布计划成立自己的新社交平台“TRUTH Social”,并通过SPAC公司DWAC上市,而Phunware的软件此前曾为特朗普竞选团队提供移动应用。最近,Creatd通过其OG画廊部门宣布了一个新的不可替代的象征性艺术下降,由特朗普的三张照片组成。NFT包括三张年轻的唐纳德·特朗普在一名模特的胸部签名时拍摄的照片。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PHUN":"Phunware, Inc.","CRTD":"Creatd Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105918886","content_text":"Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%.Donald Trump has dropped from the Forbes 400 list of the richest Americans for the first time in 25 years, according to the Forbes list. Although Trump's current value of $2.5 billion is still worthy of being called \"super rich\", he is still $400 million short of the Forbes 400 Rich List in the past.\nLast week,Trump announced plans to set up his new social platform \"TRUTH Social\" and go public through SPAC company DWAC. While Phunware's software previously provided mobile applications for Trump campaign team.And recently,Creatd announced a new non-fungible token art drop through its OG Gallery unit consisting of three photographs of Trump. The NFT includes three candid images of a young Donald Trump, captured as he signs the breast of a model.","news_type":1,"symbols_score_info":{"DWAC":0.9,"PHUN":0.9,"CRTD":0.9}},"isVote":1,"tweetType":1,"viewCount":1803,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}